Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

“Vesalius redefines how we think about and treat common illnesses including autoimmune disorders, diabetes, and neurologic ... since the first L-dopa drugs. Central to our alliance with GSK is our ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

Obesity causes insulin resistance by increasing activation of the sympathetic nervous system and the release of the stress hormone norepinephrine, according to a new study.

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

Drug distributor Cardinal Health said on Monday it will take a majority stake in gastroenterology care platform GI Alliance ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

Eledon is running a phase 2 trial of the drug in this setting, called BESTOW, that is due to generate results next year. It has been five years since Lexicon Pharma's type 1 diabetes therapy ...

DelveInsight's Glucose Syrup Market Insights report provides the current and forecast market analysis, individual leading ...

The glucose syrup market is largely driven by its rising demand within the food and beverage industry. Furthermore, the expanding uses and benefits of glucose syrup in the pharmaceutical sector ...